Ublituximab (Briumvi®). HTA ID: 24008

Assessment Status Rapid Review Complete
HTA ID 24008
Drug Ublituximab
Brand Briumvi®
Indication For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Assessment Process
Rapid review commissioned 28/02/2024
Rapid review completed 02/04/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ublituximab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.